



PRESS RELEASE

February 21, 2022

CombiGene launches new website

STOCKHOLM, February 21, 2022 — When CombiGene signed an agreement with a potential value of USD 328.5 million with Spark Therapeutics in the autumn of 2021, a major leap was taken in the company's development and established CombiGene as an internationally recognized gene therapy company.

The agreement is of course extremely important and means that the epilepsy project CG01 has now been given the very best conditions to reach all the way to global commercialization and thus reach epilepsy patients who currently lack treatment options.

The agreement also means that CombiGene has shown that the company's business model can establish partnerships among the largest players in the international pharmaceutical industry. Spark is part of the Roche Group, the world's third-largest pharmaceutical company.

To better reflect CombiGene's strengthened position, the company has recently launched a new website. The address is the same as before – combigene.com

Please visit it!

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has signed an exclusive collaboration and licensing agreement for CombiGene's CG01 project with Spark Therapeutics.

The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

For more information:

CombiGene AB (publ)

Jan Nilsson, CEO

Tel: +46 (0)704 66 31 63

jan.nilsson@combigene.com

Please read "Ingeneious", a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. INGENEIOUS and press releases are available at www.combigene.com